Dear Editor
Zosia Kmietowicz’s article dated 6 December 2022 discusses Pfizer’s press release of 1 November highlighting the results of their Matisse study of RSV vaccine given to pregnant women, and the valid reasons why the BMJ would not report it.
Six days later Pfizer disclosed results of this trial to their investors, including graphical representations of vaccine efficacy in the newborn. (1)
No data from the trial have been released in the US clinical trial registry (2) or in peer reviewed medical journals.
The Advisory Committee on Immunization Practices (ACIP) which advises the Centers for Disease Control and Prevention (CDC) in the USA meets on 23 February to discuss the safety and efficacy of this vaccine in pregnancy. (3)
There is an irony in that trial outcome data that are robust enough to enable investors to make financial decisions are apparently not suitable for sharing with the medical profession.
1) https://s28.q4cdn.com/781576035/files/doc_presentation/2022/12/B/Near-Te…
2) https://clinicaltrials.gov/ct2/show/NCT04424316
3) https://www.cdc.gov/vaccines/acip/index.html
Need-to-know basis